SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and It...
July 15 2014 - 1:32PM
Levi & Korsinsky announces that a class action lawsuit has been
commenced in the United States District Court for the District of
Massachusetts on behalf of investors who purchased Vertex
Pharmaceuticals Incorporated ("Vertex" or the "Company")
(Nasdaq:VRTX) securities between May 7, 2012 and May 29, 2012.
For more information, click here:
http://zlk.9nl.com/vertex-pharmaceuticals.
The complaint alleges that during the Class Period the Company
made false and/or misleading statements regarding the positive
nature of interim data from its Phase 2 study of the drugs VX-809
and Kalydeco.
On May 29, 2012, Vertex issued a series of press releases in
which it acknowledged that the results from its clinical trials
were not as positive as previously indicated. These results were
further restated on June 28, 2012.
If you suffered a loss in Vertex you have until July 28, 2014 to
request that the Court appoint you as lead plaintiff. Your ability
to share in any recovery doesn't require that you serve as a lead
plaintiff. To obtain additional information, contact Joseph E.
Levi, Esq. either via email at jlevi@zlk.com or by telephone at
(212) 363-7500, toll-free: (877) 363-5972, or visit
http://zlk.9nl.com/vertex-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut, and Washington D.C. The firm's 26
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits.
Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT: Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024